RxDoctor Payments Data

Joseph Peila, MD

Internal Medicine · Billings, MTNPI 1669739710

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $147,475 of the $147,725 with a category attached, or 99.8%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 98.3% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $37,901, more than ten times the $2,275 reported in 2019. Among internal medicine clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$147,725in general payments, 2019–2025

Across 63 payments — averaging $2344.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$145K
  • Shire North American Group Inc$2K
  • Novo Nordisk$163
  • Edwards Lifesciences$46
  • Inspire Medical Systems, Inc.$27
  • Lilly USA, LLC$14

What the payments were for

  • Consulting fees$147,475100%
  • Food & beverage$2500%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$147,725 in reported general payments places this provider in the 95th percentile of 244 internal medicine providers in Montana.

See all internal medicine providers in Montana

Medicare billing

Part B allowed, 2024
$21,525
Medicare patients
184
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$96,702
OzempicSemaglutide57$80,019
MounjaroTirzepatide37$45,243
TrulicityDulaglutide36$40,528
JardianceEmpagliflozin37$36,800
XareltoRivaroxaban23$22,917
Spiriva HandihalerTiotropium Bromide14$11,472
Tresiba Flextouch U-200Insulin Degludec12$7,016
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$5,628
Breo ElliptaFluticasone/Vilanterol12$5,205
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,607
Atorvastatin Calcium379$3,396
Tamsulosin Hcl158$3,250
SynthroidLevothyroxine Sodium27$2,824
Novolog FlexpenInsulin Aspart20$2,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$14$85,77173 claims
Novo NordiskOzempic$163$80,01957 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 244 internal medicine providers in Montana.

Other internal medicine in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →